Falciparum malaria, a devastating parasitic disease affecting >200 million people each year, is treated using fixed dose combination treatments, the Artemisinin Combination Therapies (ACTs) over 3 days of dosing.  The constant threat of resistance and the need to deliver alternative options to treat patients in the event of all ACTs failing, as well as the need for improved drugs against other human-infecting Plasmodium parasites, has led to MMV and its partners, in collaboration, to build up a portfolio of projects and compounds focused on the treatment and prevention of malaria.  

This talk will cover the strategy underpinning antimalarial drug discovery, the status of the current portfolio (including the attrition and delivery) alongside a summary of new innovations to accelerate antimalarial drug discovery.

Learn more on the Indian Institute of Science Education and Research website.